江西：支持符合条件的医药企业通过发行各类债券、资产证券化产品及基础设施公募REITs等拓宽融资渠道

Core Viewpoint - The Jiangxi Provincial Government has issued implementation opinions to deepen the regulation reform of pharmaceuticals, medical devices, and cosmetics, aiming to promote high-quality development in the pharmaceutical industry [1] Summary by Relevant Sections Innovation Support Mechanism - The government plans to enhance innovation support mechanisms by initiating pilot programs for R&D services in pharmaceuticals, medical devices, and cosmetics [1] - A collaborative mechanism will be established between provincial drug regulatory departments and local governments to expedite the review process for innovative products [1] Regulatory and Policy Support - A "face-to-face" service mechanism will be set up to assist enterprises and R&D institutions in developing innovative products, with a focus on key drugs and medical devices that are prioritized for expedited registration [1] - The processing time for provincial-level related matters will be reduced by 15% [1] Financial Incentives - New 1st class innovative drugs and 3rd class innovative medical devices that generate economic benefits will receive a reward of 10 million yuan each, while newly approved generic chemical drugs will receive 2 million yuan each [1] - Local governments and park management committees are encouraged to implement reward and subsidy policies for national innovative drugs and other specified categories [1] Financing and Investment - Banks are encouraged to develop credit products tailored to the pharmaceutical industry's characteristics, focusing on long-term, low-collateral, and high-credit lending [1] - The provincial modern industry guidance fund and related science and technology innovation funds will be directed towards pharmaceutical companies with listing potential [1] - Pharmaceutical companies are supported in expanding financing channels through various means, including bond issuance and asset securitization [1]